About MD Tirzepatide — A Cited Casebook of the Tirzepatide Trials

About this site

MD Tirzepatide keeps a plain-English casebook of the peer-reviewed research on tirzepatide. It is a place to read the trial record, not a place to receive care: no clinician staffs it, nothing here is diagnosed, treated, or prescribed, and no medical advice is given. It is not a pharmacy, a telehealth service, or a vendor either — it sources, supplies, and sells nothing. What it does is read the published science and write each finding down with the citation attached.

The 'MD' in our name is editorial framing — a position we occupy relative to the clinical literature. We read the trial protocols, summarise the findings, and cite our sources. We are a reading room for the SURPASS, SURMOUNT, SYNERGY-NASH, SURMOUNT-OSA, and SUMMIT trial programmes — not a healthcare practice.

Tirzepatide is an FDA-approved prescription medicine. The decision to use it is a clinical decision that belongs to a licensed prescriber and an individual patient. This site does not participate in that decision.

Every figure in the casebook is footnoted. Each quantitative claim traces to a peer-reviewed study or an authoritative regulatory source, and where the evidence base has gaps, is preclinical only, or rests on a safety signal that is theoretical rather than confirmed in humans, the entry says so.

We do not use brand names for tirzepatide in our editorial content. We use only the international nonproprietary name, as recommended in the academic literature.

This site has no affiliation with the manufacturer of tirzepatide or with any pharmaceutical company.